Neurocrine Biosciences, Inc. (NBIX) Comparison with companies in other sectors?

Neurocrine Biosciences, Inc. has a share price of 98.97M. You can analyze Neurocrine Biosciences, Inc. (NBIX) competitors across different market sectors through stock heatmaps.

What are NBIX's NET and operating margins?

Neurocrine Biosciences, Inc. (NBIX) operating margin is around 0.21, and net profit margin is approximately 0.13 as of the latest reports.

In what way does NBIX's earnings per share (EPS) trend reflect its financial momentum?

Neurocrine Biosciences, Inc. (NBIX) EPS is 2.95 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Neurocrine Biosciences, Inc. is 44.69, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Neurocrine Biosciences, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Neurocrine Biosciences, Inc. like P/E which is 43.00, P/B which is 5.19, and PEG which is -4.15. Compare them with sector averages to evaluate if the stock is priced fairly.

Neurocrine Biosciences, Inc.

NBIX•NASDAQ

Healthcare

Drug Manufacturers - Specialty & Generic

$133.02

$1.00(0.76%)

Fundamental Analysis of Neurocrine Biosciences, Inc. (NBIX)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$2.95

P/E Ratio

44.69

ROE

0.12%

Net Margin

0.13%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$13.05B

Shares OutstandingTotal number of shares issued

$98.97M

Book Value/ShareNet worth per share

$25.43

Revenue/ShareAnnual revenue per share

$24.20

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$2.95

Net MarginNet income as percentage of revenue

12.68%

Operating MarginOperating income as percentage of revenue

20.61%

ROEReturn on shareholders' equity

11.81%

ROAReturn on total assets

8.29%

ROCEReturn on capital employed

15.71%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$4.94

Cash/ShareCash and equivalents per share

$9.46

FCF YieldFree cash flow as percentage of market cap

3.77%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for NBIXFinancial Ratios Analysis details for NBIX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for NBIXSector Benchmarking details for NBIX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Neurocrine Biosciences, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Neurocrine Biosciences, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Neurocrine Biosciences, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Neurocrine Biosciences, Inc.

For Neurocrine Biosciences, Inc., essential financial indicators include EPS 2.95, PE 44.69, and ROE 0.12. These key ratios reveal insights into Neurocrine Biosciences, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Neurocrine Biosciences, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Neurocrine Biosciences, Inc.

Metrics like Net Margin 12.68% and ROA 8.29% shed light on how well Neurocrine Biosciences, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Neurocrine Biosciences, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Neurocrine Biosciences, Inc.

Using ratios such as P/B Ratio 5.19 and PEG Ratio -4.15, investors can assess whether Neurocrine Biosciences, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Neurocrine Biosciences, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Neurocrine Biosciences, Inc.

Financial health indicators, such as Debt/Equity Ratio 0.18 and Cash Flow $4.94, provide a snapshot of Neurocrine Biosciences, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Neurocrine Biosciences, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Neurocrine Biosciences, Inc.

Investing in Neurocrine Biosciences, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Neurocrine Biosciences, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;